{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:24:19Z","timestamp":1771503859936,"version":"3.50.1"},"reference-count":194,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073754"],"award-info":[{"award-number":["82073754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273840"],"award-info":[{"award-number":["82273840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20221524"],"award-info":[{"award-number":["BK20221524"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.actbio.2023.04.019","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T20:56:14Z","timestamp":1681764974000},"page":"74-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Unstructured polypeptides as a versatile drug delivery technology"],"prefix":"10.1016","volume":"164","author":[{"given":"Yue","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingkang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haichao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruilong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1529-860X","authenticated-orcid":false,"given":"Jun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2023.04.019_bib0001","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/bab.1617","article-title":"Progress in biopharmaceutical development","volume":"65","author":"Kesik-Brodacka","year":"2018","journal-title":"Biotechnol. Appl. Biochem"},{"key":"10.1016\/j.actbio.2023.04.019_bib0002","doi-asserted-by":"crossref","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagass\u00e9","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.actbio.2023.04.019_bib0003","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.actbio.2023.04.019_bib0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.actbio.2023.04.019_bib0005","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1039\/C6TB00308G","article-title":"Polymer-based nanoparticles for protein delivery: design, strategies and applications","volume":"4","author":"Zhao","year":"2016","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.actbio.2023.04.019_bib0006","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/10826068.2020.1839907","article-title":"Challenges and advancements in the pharmacokinetic enhancement of therapeutic proteins","volume":"51","author":"Khodabakhsh","year":"2021","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0007","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1039\/D0BM01151G","article-title":"Nano and microscale delivery platforms for enhanced oral peptide\/protein bioavailability","volume":"8","author":"Tong","year":"2020","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0008","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1177\/0091270011413894","article-title":"Characterizing the impact of renal impairment on the clinical pharmacology of biologics","volume":"52","author":"Meibohm","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0009","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0304-4165(03)00116-8","article-title":"Polysialylated insulin: synthesis, characterization and biological activity in vivo","volume":"1622","author":"Jain","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.actbio.2023.04.019_bib0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejpb.2014.03.010","article-title":"Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra","volume":"87","author":"Liebner","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8929715","article-title":"Protein PEGylation: navigating recombinant protein stability, aggregation, and bioactivity","volume":"2022","author":"Zuma","year":"2022","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.actbio.2023.04.019_bib0012","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ejmech.2009.11.002","article-title":"Preparation of synthetic polyoxazoline based carrier and Vibrio cholerae O-specific polysaccharide conjugate vaccine","volume":"45","author":"Farkas","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0013","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1166\/jbn.2015.2114","article-title":"Novel IL-2-poly(HPMA)nanoconjugate based immunotherapy","volume":"11","author":"Votavova","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0014","doi-asserted-by":"crossref","first-page":"14323","DOI":"10.1021\/ja504390x","article-title":"Therapeutic protein-polymer conjugates: advancing beyond PEGylation","volume":"136","author":"Pelegri-O'Day","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2023.04.019_bib0015","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/bc800242t","article-title":"Poly(2-methacryloyloxyethyl phosphorylcholine) for protein conjugation","volume":"19","author":"Lewis","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114079","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.04.019_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy."},{"key":"10.1016\/j.actbio.2023.04.019_bib0018","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3390\/molecules23071700","article-title":"Understanding the role of anti-PEG antibodies in the complement activation by Doxil in vitro","volume":"23","author":"Neun","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.actbio.2023.04.019_bib0019","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"10","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.actbio.2023.04.019_bib0020","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"23","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.actbio.2023.04.019_bib0021","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V93.6.2025.406k19_2025_2032","article-title":"Tandem amino acid repeats from Trypanosoma cruzi shed antigens increase the half-life of proteins in blood","volume":"93","author":"Buscaglia","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0022","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/514199","article-title":"The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain","volume":"177","author":"Buscaglia","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.actbio.2023.04.019_bib0023","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1146\/annurev-food-031414-111800","article-title":"collagen and gelatin","volume":"6","author":"Liu","year":"2015","journal-title":"Annu. Rev. Food Sci. Technol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0024","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.addr.2003.08.008","article-title":"Recombinant collagen and gelatin for drug delivery","volume":"55","author":"Olsen","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.04.019_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00146","article-title":"Phase III randomized trial of maintenance taxanes versus surveillance in women with advanced ovarian\/tubal\/peritoneal cancer: a gynecologic oncology group 0212:NRG oncology study","author":"Copeland","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0026","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/COC.0b013e31826e0550","article-title":"Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer","volume":"37","author":"Northfelt","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0027","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/protein\/gzm020","article-title":"Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life","volume":"20","author":"Schlapschy","year":"2007","journal-title":"Protein Eng. Des. el. PEDS"},{"key":"10.1016\/j.actbio.2023.04.019_bib0028","unstructured":"M. Besman, S. Chipman, D. Leung, J. Singer, Conjugates of biologically active proteins having a modified in vivo half-life, US 2009\/0298762 A1."},{"key":"10.1016\/j.actbio.2023.04.019_bib0029","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nbt.1588","article-title":"A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner","volume":"27","author":"Schellenberger","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0030","doi-asserted-by":"crossref","first-page":"e10175","DOI":"10.1371\/journal.pone.0010175","article-title":"Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose","volume":"5","author":"Geething","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2023.04.019_bib0031","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/jps.23229","article-title":"A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life","volume":"101","author":"Cleland","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0032","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/protein\/gzt023","article-title":"PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins","volume":"26","author":"Schlapschy","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.actbio.2023.04.019_bib0033","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cocis.2017.06.004","article-title":"PASylation\u00ae: a versatile technology to extend drug delivery","volume":"31","author":"Binder","year":"2017","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39776-0","article-title":"Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology","volume":"9","author":"Aghaabdollahian","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2023.04.019_bib0035","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bph.13499","article-title":"Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity","volume":"173","author":"Yin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biochi.2018.05.020","article-title":"Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis","volume":"151","author":"Yin","year":"2018","journal-title":"Biochimie"},{"key":"10.1016\/j.actbio.2023.04.019_bib0037","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/15100","article-title":"Purification of recombinant proteins by fusion with thermally-responsive polypeptides","volume":"17","author":"Meyer","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0038","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0079-6107(92)90003-O","article-title":"Free energy transduction in polypeptides and proteins based on inverse temperature transitions","volume":"57","author":"Urry","year":"1992","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0039","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nchem.2715","article-title":"Programming molecular self-assembly of intrinsically disordered proteins containing sequences of low complexity","volume":"9","author":"Simon","year":"2017","journal-title":"Nat. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0040","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpb.2009.12.002","article-title":"Engineering a pharmacologically superior form of granulocyte-colony-stimulating factor by fusion with gelatin-like-protein polymer","volume":"74","author":"Huang","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0041","first-page":"4269","article-title":"Paclitaxel and water-soluble poly (L-glutamic acid)-paclitaxel, induce direct chromosomal abnormalities and cell death in a murine metastatic melanoma cell line","volume":"17","author":"Multani","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1016\/j.actbio.2023.04.019_bib0042","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/bp00016a012","article-title":"Production and purification of a recombinant elastomeric polypeptide, G-(VPGVG)19-VPGV, from Escherichia coli","volume":"8","author":"Mcpherson","year":"1992","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.actbio.2023.04.019_bib0043","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1210\/en.2015-1519","article-title":"Long-acting PASylated leptin ameliorates obesity by promoting satiety and preventing hypometabolism in leptin-deficient Lepob\/ob mice","volume":"157","author":"Bolze","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.actbio.2023.04.019_bib0044","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2006.07.022","article-title":"A thermally responsive biopolymer for intra-articular drug delivery","volume":"115","author":"Betre","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0045","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0046","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2013-1437","article-title":"A long-ccting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone\u2013deficient adults","volume":"98","author":"Yuen","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.actbio.2023.04.019_bib0047","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/protein\/gzt048","article-title":"Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer","volume":"26","author":"Podust","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.actbio.2023.04.019_bib0048","doi-asserted-by":"crossref","first-page":"e23069","DOI":"10.1002\/bip.23069","article-title":"The polypeptide biophysics of proline\/alanine-rich sequences (PAS): recombinant biopolymers with PEG-like properties","volume":"109","author":"Breibeck","year":"2018","journal-title":"Biopolymers"},{"key":"10.1016\/j.actbio.2023.04.019_bib0049","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/acs.bioconjchem.6b00369","article-title":"PASylated coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced anti-hemolytic activity in vitro","volume":"27","author":"Kuhn","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0050","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1021\/mp5007147","article-title":"PASylation of murine leptin leads to extended plasma half-life and enhanced in vivo efficacy","volume":"12","author":"Morath","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0051","first-page":"2673","article-title":"Protein tandem repeats-the more perfect, the less structured","volume":"277","author":"Jorda","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.actbio.2023.04.019_bib0052","doi-asserted-by":"crossref","first-page":"13392","DOI":"10.1073\/pnas.1304749110","article-title":"Conformations of intrinsically disordered proteins are influenced by linear sequence distributions of oppositely charged residues","volume":"110","author":"Das","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2023.04.019_bib0053","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.10.038","article-title":"Extension of in vivo half-life of biologically active molecules by XTEN protein polymers","volume":"240","author":"Podust","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0054","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jconrel.2020.08.065","article-title":"Temperature-triggered micellization of interferon alpha-diblock copolypeptide conjugate with enhanced stability and pharmacology","volume":"328","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0055","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2020.08.004","article-title":"Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life","volume":"327","author":"Brandl","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0056","article-title":"Thermoresponsive and protease-cleavable interferon-polypeptide conjugates with spatiotemporally programmed two-step release kinetics for tumor therapy","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0057","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2019.06.030","article-title":"Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins","volume":"307","author":"Brandl","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0058","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jconrel.2018.03.015","article-title":"Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action","volume":"277","author":"Gilroy","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0059","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/acssynbio.7b00400","article-title":"Engineering extracellular expression systems in escherichia coli based on transcriptome analysis and cell growth state","volume":"7","author":"Gao","year":"2018","journal-title":"ACS Synth. Biol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0060","first-page":"30","article-title":"High-yield production of pasylated human growth hormone using secretory E. coli technology","volume":"11","author":"Cesare","year":"2013","journal-title":"Bioprocess Int."},{"key":"10.1016\/j.actbio.2023.04.019_bib0061","first-page":"1","article-title":"XTEN as biological alternative to PEGylation allows complete expression of a protease-activatable killin-based cytostatic","volume":"11","author":"Cytostatic","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2023.04.019_bib0062","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1515\/hsz-2017-0207","article-title":"Selection of an Anticalin\u00ae against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models","volume":"399","author":"Friedrich","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0063","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.113.128108","article-title":"XTEN-annexin a5: XTEN allows complete expression of long-circulating protein-based imaging probes as recombinant alternative to pegylation","volume":"55","author":"Haeckel","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0064","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202200079","article-title":"Direct affinity purification of long-acting PASylated proteins with therapeutic potential using L-prolinamide for mild elution","volume":"61","author":"Schilz","year":"2022","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.actbio.2023.04.019_bib0065","doi-asserted-by":"crossref","first-page":"e50630","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model","volume":"7","author":"Alters","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2023.04.019_bib0066","doi-asserted-by":"crossref","DOI":"10.1002\/biot.201900385","article-title":"PASylation enhances the stability, potency, and plasma half-life of interferon \u03b1-2a: a molecular dynamics simulation","volume":"15","author":"Shamloo","year":"2020","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.actbio.2023.04.019_bib0067","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S0021-9258(17)49941-8","article-title":"PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystalinduced peritonitis","volume":"295","author":"Powers","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0068","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10930-017-9699-9","article-title":"Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties","volume":"36","author":"Hedayati","year":"2017","journal-title":"Protein J."},{"key":"10.1016\/j.actbio.2023.04.019_bib0069","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2019.03.016","article-title":"Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery","volume":"452","author":"Yin","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.actbio.2023.04.019_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-017-0078","article-title":"One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer","volume":"1","author":"Luginbuhl","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.actbio.2023.04.019_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120447","article-title":"Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy","volume":"264","author":"Liang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2023.04.019_bib0072","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1007\/s00204-021-03094-0","article-title":"1062P EGFR-XPAT, a novel pro-drug T-cell engager (TCEs) engineered to address on-target, off-tumour toxicity and an orthogonal approach for cancer immunotherapy in EGFR, KRAS\/BRAF cancers","volume":"95","author":"K\u00f6hler","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0073","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1089\/thy.2019.0670","article-title":"Development of a chimeric Fab directed against human galectin-3 and validation as an immuno-PET tracer for the sensitive in vivo imaging of thyroid cancer","volume":"30","author":"Peplau","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.actbio.2023.04.019_bib0074","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.7150\/thno.38968","article-title":"Development of a high affinity Anticalin\u00ae directed against human CD98hc for theranostic applications","volume":"10","author":"Deuschle","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2023.04.019_bib0075","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1080\/21691401.2017.1369426","article-title":"Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties","volume":"46","author":"Khodabakhsh","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0076","doi-asserted-by":"crossref","first-page":"29014","DOI":"10.1074\/jbc.M114.602474","article-title":"Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis","volume":"289","author":"Harari","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0077","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/19420862.2019.1626652","article-title":"Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4","volume":"11","author":"Griffiths","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.actbio.2023.04.019_bib0078","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4161\/19420862.2014.985522","article-title":"High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation","volume":"7","author":"Mendler","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.actbio.2023.04.019_bib0079","first-page":"1971","article-title":"Tumor uptake of anti-CD20 Fabs depends on tumor perfusion","author":"Perfusion","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0080","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2967\/jnumed.114.149690","article-title":"89Zr-labeled versus 124I-labeled \u03b1HER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo","volume":"56","author":"Mendler","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0081","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1021\/acs.biomac.5b01446","article-title":"Improved doxorubicin encapsulation and pharmacokinetics of Ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements","volume":"17","author":"Falvo","year":"2016","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2023.04.019_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112515","article-title":"Improved stability and pharmacokinetics of wogonin through loading into PASylated ferritin","volume":"216","author":"Yang","year":"2022","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.actbio.2023.04.019_bib0083","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2016.08.010","article-title":"Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness","volume":"239","author":"Fracasso","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0084","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/ijms18071555","article-title":"Therapeutic efficacy of the novel stimuli-sensitive nano-Ferritins containing doxorubicin in a head and neck cancel model","volume":"18","author":"Damiani","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2018.02.025","article-title":"The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity","volume":"275","author":"Falvo","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0086","doi-asserted-by":"crossref","first-page":"18464","DOI":"10.1038\/s41598-020-74549-0","article-title":"Improvement of Certolizumab Fab\u2032 properties by PASylation technology","volume":"10","author":"Mazaheri","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2023.04.019_bib0087","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.molmet.2016.07.012","article-title":"Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity","volume":"5","author":"Chhabra","year":"2016","journal-title":"Mol. Metab."},{"key":"10.1016\/j.actbio.2023.04.019_bib0088","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1007\/s00125-016-4004-6","article-title":"Treatment of diet-induced lipodystrophic C57BL\/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation","volume":"59","author":"Bolze","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.actbio.2023.04.019_bib0089","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00253-016-7944-3","article-title":"PASylation technology improves recombinant interferon-\u03b21b solubility, stability, and biological activity","volume":"101","author":"Zvonova","year":"2017","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nano.2019.02.024","article-title":"Surface protein engineering increases the circulation time of a cell membrane-based nanotherapeutic","volume":"18","author":"Krishnamurthy","year":"2019","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0091","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007246","article-title":"Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication","volume":"14","author":"Nganou-Makamdop","year":"2018","journal-title":"PLOS Pathog."},{"key":"10.1016\/j.actbio.2023.04.019_bib0092","doi-asserted-by":"crossref","first-page":"46118","DOI":"10.1021\/acsomega.2c04071","article-title":"PASylated urate oxidase enzyme: enhancing biocatalytic activity, physicochemical properties, and plasma half-life","volume":"7","author":"Najjari","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.actbio.2023.04.019_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115473","article-title":"The anticancer effect of PASylated calreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy","volume":"210","author":"Zhang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0094","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1039\/D1SC05243H","article-title":"A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides \u2020","volume":"13","author":"Zacharias","year":"2022","journal-title":"Chem. Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0095","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0096","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2021.07.022","article-title":"Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI","volume":"337","author":"Nomani","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0097","first-page":"1","article-title":"Long\u2011circulating XTEN864\u2011annexin A5 fusion protein for phosphatidylserine\u2011related therapeutic applications","author":"Haeckel","year":"2021","journal-title":"Apoptosis (London)"},{"key":"10.1016\/j.actbio.2023.04.019_bib0098","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/bc500215m","article-title":"Multivalent antiviral XTEN-peptide conjugates with long in vivo half-life and enhanced solubility","volume":"25","author":"Ding","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119313","article-title":"Novel XTENylated AWRK6 analog with hypoglycemic activity, and anti-HSV-2 potential in combination with double shRNA","volume":"274","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0100","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0101","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acs.biomac.0c01468","article-title":"U. States, Intra-lacrimal sustained delivery of Rapamycin shows therapeutic effects without systemic toxicity in a mouse model of autoimmune dacryoadenitis characteristic of Sj\u00f6gren's Syndrome","volume":"22","author":"Ju","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2023.04.019_bib0102","first-page":"2358","article-title":"Molecular targeting of immunosuppressants using a bifunctional elastin-like polypeptide","volume":"30","author":"Lemon","year":"2019","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.actbio.2023.04.019_bib0103","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1021\/acs.molpharmaceut.9b00263","article-title":"Berunda polypeptides: biheaded Rapamycin carriers for subcutaneous treatment of autoimmune dry eye disease","volume":"16","author":"Lee","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0104","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ejpb.2014.05.016","article-title":"Elastin-like polypeptides: the influence of its molecular weight on local hyperthermia-induced tumor accumulation","volume":"88","author":"Ryu","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0105","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1002\/adma.201503440","article-title":"Enhancing pharmacokinetics, tumor accumulation, and antitumor efficacy by elastin-like polypeptide fusion of interferon alpha","volume":"27","author":"Hu","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2023.04.019_bib0106","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pep.2018.08.012","article-title":"Half-life extension of porcine interferon-\u03b1 by fusion to the IgG-binding domain of streptococcal G protein","volume":"153","author":"Zong","year":"2019","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.actbio.2023.04.019_bib0107","first-page":"139","article-title":"Anti-CD99 scFv-ELP nanoworms for the treatment of acute myeloid leukemia","volume":"176","author":"Lener","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.actbio.2023.04.019_bib0108","first-page":"317","article-title":"Anti-FLT3 nanoparticles for acute myeloid leukemia preclinical pharmacology and pharmacokinetics","author":"Park","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11100542","article-title":"Utilizing a kidney-targeting peptide to improve renal deposition of a pro-angiogenic protein biopolymer","volume":"11","author":"Mahdi","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2023.04.019_bib0110","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biomaterials.2018.11.012","article-title":"Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery","volume":"192","author":"Banskota","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2023.04.019_bib0111","first-page":"183","article-title":"A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sj\u00f6gren's Syndrome","volume":"292","author":"Hamm-alvarez","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2018.05.014","article-title":"Intra-vitreal \u03b1B crystallin fused to elastin-like polypeptide provides neuroprotection in a mouse model of age-related macular degeneration","volume":"283","author":"Sreekumar","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0113","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/acs.bioconjchem.7b00469","article-title":"Bifunctional elastin-like polypeptide nanoparticles bind rapamycin and integrins and suppress tumor growth in vivo","volume":"28","author":"Dhandhukia","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/1061186X.2017.1289537","article-title":"Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells","volume":"25","author":"Opa\u010dak-Bernardi","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.actbio.2023.04.019_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-015-0708-6","article-title":"Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer","volume":"32","author":"Iglesias","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13221-014-0026-3","article-title":"Growth factor purification and delivery systems (PADS) for therapeutic angiogenesis","volume":"7","author":"George","year":"2015","journal-title":"Vasc. Cell."},{"key":"10.1016\/j.actbio.2023.04.019_bib0117","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10989-012-9295-y","article-title":"Anticancer activity of proapoptotic peptides is highly improved by thermal targeting using elastin-like polypeptides","volume":"18","author":"Moktan","year":"2012","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.actbio.2023.04.019_bib0118","doi-asserted-by":"crossref","first-page":"e55104","DOI":"10.1371\/journal.pone.0055104","article-title":"Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model","volume":"8","author":"Bidwell","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.actbio.2023.04.019_bib0119","first-page":"1","article-title":"Unexpected multivalent display of proteins by temperature triggered self-assembly of elastin-like polypeptide block copolymers","volume":"23","author":"Donahoe","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0120","first-page":"748","article-title":"An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration","volume":"33","author":"Shamji","year":"2008"},{"key":"10.1016\/j.actbio.2023.04.019_bib0121","series-title":"European Association for the Study of Diabetes (EASD) 48th Annual Meeting, Berlin, Germany","article-title":"Safety, pharmacokinetics, and pharmacodynamics of a single subcutaneous dose of VRS-859 in patients with type 2 diabetes","author":"Cleland","year":"2012"},{"key":"10.1016\/j.actbio.2023.04.019_bib0122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0123","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0124","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0125","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/hae.13561","article-title":"BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies","volume":"24","author":"Shah","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.actbio.2023.04.019_bib0126","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcm6040039","article-title":"Outcome of clinical trials with new extended half-life FVIII\/IX concentrates","volume":"6","author":"Mancuso","year":"2017","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0127","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/2040620718796429","article-title":"Practical aspects of extended half-life products for the treatment of haemophilia","volume":"9","author":"Lambert","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0128","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1210\/jc.2015-3279","article-title":"A randomized safety and efficacy study of Somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency","volume":"101","author":"Moore","year":"2016","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"10.1016\/j.actbio.2023.04.019_bib0129","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202102795","article-title":"Combinatorial use of therapeutic ELP-based micelle particles in tissue engineering","volume":"11","author":"Bulutoglu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2023.04.019_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.aaz9890","article-title":"Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia","volume":"6","author":"Gilroy","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.actbio.2023.04.019_bib0131","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/ja0764862","article-title":"Temperature triggered self-assembly of polypeptides into multivalent spherical micelles","volume":"130","author":"Dreher","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2023.04.019_bib0132","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3109\/08923973.2014.945126","article-title":"Development trends for generation of single-chain antibody fragments","volume":"36","author":"Farajnia","year":"2014","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0133","series-title":"Marketed Therapeutic Antibodies Compendium","author":"Reichert","year":"2012"},{"key":"10.1016\/j.actbio.2023.04.019_bib0134","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.22775","article-title":"Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells","volume":"5","author":"Marcucci","year":"2013","journal-title":"MAbs"},{"key":"10.1016\/j.actbio.2023.04.019_bib0136","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/nn403973g","article-title":"A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody","volume":"8","author":"Aluri","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2023.04.019_bib0137","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.actbio.2023.04.019_bib0138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-86641-0","article-title":"Effective rational humanization of a PASylated anti\u2011galectin\u20113 Fab for the sensitive PET imaging of thyroid cancer in vivo","volume":"11","author":"Peplau","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2023.04.019_bib0139","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1158\/0008-5472.CAN-15-3046","article-title":"Noninvasive in vivo imaging and biologic characterization of thyroid tumors by immunoPET targeting of Galectin-3","volume":"76","author":"D'Alessandria","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2023.04.019_bib0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/bc800351m","article-title":"Synthesis and evaluation of multivalent branched HPMA copolymer-Fab\u2019 conjugates targeted to the B-cell antigen CD20","volume":"20","author":"Johnson","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0141","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1389-0344(01)00090-9","article-title":"Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting","volume":"18","author":"Kortt","year":"2001","journal-title":"Biomol. Eng."},{"key":"10.1016\/j.actbio.2023.04.019_bib0142","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/protein\/13.8.565","article-title":"ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers","volume":"13","author":"Dolezal","year":"2000","journal-title":"Protein Eng."},{"key":"10.1016\/j.actbio.2023.04.019_bib0143","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.1180","article-title":"1060P HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted safety margins in non-human primate (NHP)","volume":"31","author":"Cattaruzza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0144","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1111\/j.1742-4658.2008.06439.x","article-title":"Alternative binding proteins: anticalins-harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities","volume":"275","author":"Skerra","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.actbio.2023.04.019_bib0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.febslet.2013.11.006","article-title":"Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins","volume":"588","author":"Richter","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.actbio.2023.04.019_bib0146","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.03.002","article-title":"Bioengineered protein-based nanocage for drug delivery","volume":"106","author":"Lee","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.04.019_bib0147","doi-asserted-by":"crossref","DOI":"10.3390\/genes9070370","article-title":"Bioengineering strategies for protein-based nanoparticles","volume":"9","author":"Diaz","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.actbio.2023.04.019_bib0148","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2022.102757","article-title":"Liposomes as biocompatible and smart delivery systems - the current state","volume":"309","author":"Dymek","year":"2022","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0149","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: the phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2023.04.019_bib0150","article-title":"PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: an alternative to PEGylation","volume":"47","author":"Zhang","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2023.04.019_bib0151","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/IJN.S152485","article-title":"Targeting prostate cancer cells with hybrid elastin-like polypeptide\/liposome nanoparticles","volume":"13","author":"Zhang","year":"2018","journal-title":"Int. J. Nanomedicine."},{"key":"10.1016\/j.actbio.2023.04.019_bib0152","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.colsurfb.2011.10.051","article-title":"Elastin-like polypeptide modified liposomes for enhancing cellular uptake into tumor cells","volume":"91","author":"Na","year":"2012","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.actbio.2023.04.019_bib0153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7150\/thno.11852","article-title":"Cell or cell membrane-based drug delivery systems","volume":"5","author":"Tan","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.actbio.2023.04.019_bib0154","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nano.2018.08.002","article-title":"Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE(-\/-)) mice","volume":"15","author":"Song","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.actbio.2023.04.019_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114238","article-title":"Why nanoparticles prefer liver macrophage cell uptake in vivo","volume":"185","author":"Ngo","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.04.019_bib0156","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ejpb.2008.06.015","article-title":"PEGylated chitosan-based polymer micelle as an intracellular delivery carrier for anti-tumor targeting therapy","volume":"70","author":"Hu","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.actbio.2023.04.019_bib0157","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jconrel.2022.04.022","article-title":"Tailored protein-conjugated DNA nanoplatform for synergistic cancer therapy","volume":"346","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0158","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1073\/pnas.0913192107","article-title":"Binding and uptake of H-ferritin are mediated by human transferrin receptor-1","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2023.04.019_bib0159","doi-asserted-by":"crossref","first-page":"14900","DOI":"10.1073\/pnas.1407808111","article-title":"H-ferritin-nanocaged doxorubicin nanoparticles specifically target and kill tumors with a single-dose injection","volume":"111","author":"Liang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2023.04.019_bib0160","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V60.4.827.827","article-title":"The clearance of 131I-human plasma ferritin in man","volume":"60","author":"Worwood","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2023.04.019_bib0161","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.actbio.2023.04.019_bib0162","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1021\/acsnano.0c06136","article-title":"DNA nanostructures: current challenges and opportunities for cellular delivery","volume":"15","author":"Lacroix","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2023.04.019_bib0163","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4155\/fmc.15.108","article-title":"Enhancing the pharmacokinetic\/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems","volume":"7","author":"Lin","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0164","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.addr.2020.10.019","article-title":"Robust and smart polypeptide-based nanomedicines for targeted tumor therapy","volume":"160","author":"Deng","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2023.04.019_bib0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2017.08.049","article-title":"Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy","volume":"142","author":"Joubert","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0166","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1\u00a0\u00d7\u00a0CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0167","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10637-007-9053-8","article-title":"A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance","volume":"25","author":"Bidwell","year":"2007","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.actbio.2023.04.019_bib0168","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/pharmaceutics11100543","article-title":"Active cellular and subcellular targeting of nanoparticles for drug delivery","volume":"11","author":"Nag","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.actbio.2023.04.019_bib0169","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-3659(03)00216-5","article-title":"Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy","volume":"91","author":"Dreher","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0170","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2005.10.006","article-title":"Structural optimization of a \u201csmart\u201d doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors","volume":"110","author":"Furgeson","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2023.04.019_bib0171","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature16057","article-title":"Novel antibody-antibiotic conjugate eliminates intracellular S.aureus","volume":"527","author":"Lehar","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2023.04.019_bib0172","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0173","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.actbio.2023.04.019_bib0174","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2023.04.019_bib0175","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1158\/0008-5472.CAN-15-0129","article-title":"A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy","volume":"75","author":"Yurkovetskiy","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.actbio.2023.04.019_bib0176","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.actbio.2023.04.019_bib0177","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nchembio847","article-title":"Natural expansion of the genetic code","volume":"3","author":"Ambrogelly","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0178","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1073\/pnas.1004213107","article-title":"Charges in the hydrophobic interior of proteins","volume":"107","author":"Isom","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.actbio.2023.04.019_bib0179","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/B978-0-12-396962-0.00012-4","article-title":"Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells","volume":"503","author":"Thompson","year":"2012","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0180","doi-asserted-by":"crossref","first-page":"17234","DOI":"10.1021\/jacs.8b10299","article-title":"Potent protein delivery into mammalian cells via a supercharged polypeptide","volume":"140","author":"Yin","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.actbio.2023.04.019_bib0181","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1021\/acs.bioconjchem.9b00022","article-title":"Microenvironment-responsive delivery of the Cas9 RNA-guided endonuclease for efficient genome editing","volume":"30","author":"Yin","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.actbio.2023.04.019_bib0182","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1021\/acs.nanolett.1c01190","article-title":"Cytosolic protein delivery for intracellular antigen targeting using supercharged polypeptide delivery platform","volume":"21","author":"Wang","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.actbio.2023.04.019_bib0183","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1016\/j.biomaterials.2013.02.038","article-title":"Enhancing cellular uptake of GFP via unfolded supercharged protein tags","volume":"34","author":"Pesce","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2023.04.019_bib0184","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1083\/jcb.127.5.1217","article-title":"Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules","volume":"127","author":"Schnitzer","year":"1994","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0185","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0969-2126(03)00185-0","article-title":"Enhancing protein crystallization through precipitant synergy","volume":"11","author":"Majeed","year":"2003","journal-title":"Structure"},{"key":"10.1016\/j.actbio.2023.04.019_bib0186","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1107\/S2053230X20008328","article-title":"Proline\/alanine-rich sequence (PAS) polypeptides as an alternative to PEG precipitants for protein crystallization","volume":"76","author":"Schiefner","year":"2020","journal-title":"Acta Crystallogr. Sect. F"},{"key":"10.1016\/j.actbio.2023.04.019_bib0187","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/adhm.201400781","article-title":"Fabricated elastin","volume":"4","author":"Yeo","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2023.04.019_bib0188","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1021\/acs.biomac.2c01001","article-title":"Tunable physicomechanical and drug release properties of in situ forming thermoresponsive elastin-like polypeptide hydrogels","volume":"23","author":"Lee","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.actbio.2023.04.019_bib0189","doi-asserted-by":"crossref","first-page":"e1450","DOI":"10.1002\/term.2562","article-title":"Biocompatibility of two model elastin-like recombinamer-based hydrogels formed through physical or chemical cross-linking for various applications in tissue engineering and regenerative medicine","volume":"12","author":"Ib\u00e1\u00f1ez-Fonseca","year":"2018","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.actbio.2023.04.019_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.201900142","article-title":"Drug-loaded elastin-like polypeptide\u2013collagen hydrogels with high modulus for bone tissue engineering","volume":"19","author":"Pal","year":"2019","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.actbio.2023.04.019_bib0191","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nmat4118","article-title":"Designer amphiphilic proteins as building blocks for the intracellular formation of organelle-like compartments","volume":"14","author":"Huber","year":"2015","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2023.04.019_bib0192","doi-asserted-by":"crossref","first-page":"36998","DOI":"10.1021\/acsami.2c05268","article-title":"Dynamic compartmentalization of peptide-oligonucleotide conjugates with reversible nanovesicle-microdroplet phase transition behaviors","volume":"14","author":"Wang","year":"2022","journal-title":"ACS Appl. Mater. Interfaces."},{"key":"10.1016\/j.actbio.2023.04.019_bib0193","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102495","article-title":"Protein structure prediction in the deep learning era","volume":"77","author":"Peng","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.actbio.2023.04.019_bib0194","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41392-023-01381-z","article-title":"AlphaFold2 and its applications in the fields of biology and medicine","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706123002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:04:50Z","timestamp":1761674690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706123002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":194,"alternative-id":["S1742706123002106"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2023.04.019","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unstructured polypeptides as a versatile drug delivery technology","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2023.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}